Rare Diseases

Rare Diseases Perspective

 

Rare Diseases News & Journal Articles

  • Recordati to Seek Canadian Approval for Kidney Disease Drug Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma, which makes the only drug approved for treatment in Canada.
  • Biogen SMA Drug Price, Novartis Estimates for Its Treatment Far Too High -U.S. Group Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.
 

Medscape Editorial Collaborations

also read

viagra 100mg

https://steroid-pharm.com